STAT

Opinion: Data analysts: a new kind of whistleblower to ‘catch a rogue’?

The groundwork has been laid for a new kind of whistleblower — data analysts — and for a broader challenge to the traditional concept of what it means to be…

Most whistleblower cases, regardless of industry, emerge through the bravery and integrity of an employee coming forward to shine a light on misconduct they have witnessed firsthand. But a new kind of whistleblower is emerging: the data-driven whistleblower.

They aren’t necessarily at the scene of the crime but instead figure it out after the fact through tedious number crunching and analysis.

Two pending cases, one in California and the other in Texas, that both focus was designed to promote.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks